Emerging focus on integrated cardiovascular-kidney-metabolic care reshapes NHS approach

A shift towards a cohesive cardiovascular-kidney-metabolic framework is prompting NHS service redesigns, emphasising early detection, broader treatment strategies, and addressal of health disparities amidst growing recognition of interconnected chronic conditions.

Cardiovascular-kidney-metabolic care is emerging as a more realistic way to think about chronic disease, because the heart, kidneys and metabolism so often fail together rather than separately. The American Heart Association describes cardiovascular-kidney-metabolic health as an interconnected system in which heart disease, kidney disease, obesity and diabetes are closely linked, while its professional resources stress the need for early detection and coordinated treatment. That framework is increasingly relevant to the NHS, where service delivery still tends to be organised around single diseases and separate clinics.

The case for a joined-up approach is not merely semantic. According to the British Journal of Cardiology article by Rani Khatib, a coherent cardiovascular-kidney-metabolic, or CVKM, mindset is about changing clinical reasoning as much as terminology. It reflects the reality that common risk factors such as obesity, smoking, poor diet, inactivity, hypertension, dysglycaemia, dyslipidaemia and kidney dysfunction tend to cluster, creating a web of risk that is missed when clinicians focus on one organ system at a time.

That argument has been strengthened by policy. NHS England and the Department of Health and Social Care’s cardiovascular disease modern service framework explicitly adopts a cardiovascular-kidney-metabolic approach, saying these conditions and risk factors should be identified and managed together. The American Heart Association and the American College of Cardiology have also issued what they describe as the first clinical practice guideline on cardiovascular-kidney-metabolic syndrome, using staging to assess the heart, kidneys and metabolism across the life course.

The practical problem, however, is that most care is still delivered in fragments. Patients may be reviewed separately for blood pressure, lipids, diabetes, weight, kidney function and symptoms, even when the underlying pathology is overlapping. Khatib argues that this can produce duplication, mixed messages and therapeutic inertia, while the AHA’s own materials acknowledge that these conditions are often treated separately despite their close links.

A more coherent model would shift the emphasis from ticking off individual disease targets to prioritising what is most likely to improve overall prognosis and lessen treatment burden. That matters because people with multiple long-term conditions often do not resemble the selected trial populations on which many guidelines are based. The AHA’s framework, together with the NHS service framework, points towards broader assessment, earlier prevention and coordinated decisions rather than isolated disease management.

The article also highlights the growing importance of therapies that cut across traditional specialty boundaries. Drugs such as glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors were first known for glucose control, but are now valued for wider cardiovascular, renal and metabolic benefits. The AHA’s materials and the first joint guideline both reflect this shift towards treatments that can influence several systems at once.

Khatib says any serious CVKM model must also address equity, mental health and sex-specific gaps, not just physiology. The article notes that mental illness, deprivation and structural barriers are associated with poorer outcomes, and that women remain under-recognised in some cardiovascular pathways. The AHA’s wider CKM initiative similarly frames the issue as whole-person care, not simply the bundling of diseases into a new label.

Service redesign, the article argues, should therefore focus on shared pathways, clearer professional roles and neighbourhood-based care, with primary care acting as the coordinating centre and specialist services supporting more complex cases. The NHS framework’s emphasis on care closer to home and reducing unwarranted variation fits that direction of travel, while the AHA initiative likewise calls for integrated care resources for both patients and clinicians. The article’s larger point is that modern science has moved faster than service delivery, and that the next step is to align consultations, incentives and accountability with the reality of interconnected disease.